Lykke

Indie Games Burst Onto Nintendo Switch Promising Adventure, Cozy Vibes, and Curious Cat Mischief

Retrieved on: 
Wednesday, April 17, 2024
Technology, Electronic Games, Entertainment, Online, Mobile Entertainment, Software, General Entertainment, Hardware, Consumer Electronics, Licensing (Entertainment), Lykke, Personality, Foot Clan, Destiny, Publishing, Assemble, Ground substance, Zee, Vainglory (video game), Travel, SteamWorld, Cat Quest, Future Friends, News, Sayonara Wild Hearts, Annapurna Interactive, Animal, Series, Hand, Weapon, Teenage Mutant Ninja Turtles, Moon, WayForward, Personality test, PLAYISM, ANIMAL, Foot, Nintendo Direct, Nintendo eShop, Light, Atari, Multimedia, Internet access, Indie, Nintendo Switch, SteamWorld Heist, Zephyr, Friends, DLC, Nintendo Switch Online, Video game

View the full release here: https://www.businesswire.com/news/home/20240417156103/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240417156103/en/
    Little Kitty, Big City releases on Nintendo Switch on May 9.
  • The Purribean is yours to explore when Cat Quest III launches for Nintendo Switch on Aug. 8.
  • For the latest news and updates about indie games on Nintendo Switch, follow the Indie World X account @IndieWorldNA and check out https://www.nintendo.com/us/indie-world/news/ .
  • * Any Nintendo Switch Online membership (sold separately) and Nintendo Account required for online features.

BioInnovation Institute welcomes innovative smartRNA project to Bio Studio program

Retrieved on: 
Thursday, March 14, 2024
Lykke, Epilepsy, EUR, KU Leuven, European Molecular Biology Laboratory, Haploinsufficiency, Genetics, Patient, Research, RNA, University of Washington, University, Messenger, Cancer, Laboratory, BII, Imperial College London, Student, EMBL, Monogenic, Aarhus University, University of Copenhagen, Intellectual property, Therapy, Molecular biology, DSM-IV codes, Disorder, Vaccine

Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.

Key Points: 
  • Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.
  • During the 3-year BII Bio Studio program, the objective of smartRNA is to deliver an in vitro proof-of-concept, a pseudo in vivo proof-of-principle, and in vitro benchmarking against established technologies.
  • Anja Mølhart Høg, Entrepreneur-in-Residence heading up the smartRNA project, added: "We are excited to welcome the smartRNA project to BII's Bio Studio program.
  • The Bio Studio program is a recently established BII program with the ambition to build and run a leading life science company creation facility in Europe.

BioInnovation Institute welcomes innovative smartRNA project to Bio Studio program

Retrieved on: 
Thursday, March 14, 2024
Lykke, Epilepsy, EUR, KU Leuven, European Molecular Biology Laboratory, Haploinsufficiency, Genetics, Patient, Research, RNA, University of Washington, University, Messenger, Cancer, Laboratory, BII, Imperial College London, Student, EMBL, Monogenic, Aarhus University, University of Copenhagen, Intellectual property, Therapy, Molecular biology, DSM-IV codes, Disorder, Vaccine

Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.

Key Points: 
  • Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.
  • During the 3-year BII Bio Studio program, the objective of smartRNA is to deliver an in vitro proof-of-concept, a pseudo in vivo proof-of-principle, and in vitro benchmarking against established technologies.
  • Anja Mølhart Høg, Entrepreneur-in-Residence heading up the smartRNA project, added: "We are excited to welcome the smartRNA project to BII's Bio Studio program.
  • The Bio Studio program is a recently established BII program with the ambition to build and run a leading life science company creation facility in Europe.

CGI and Körber announce global partnership to enable pharmaceutical and life sciences clients to improve production operations

Retrieved on: 
Monday, January 22, 2024
Lykke, Senior, Research, GIB, Health, Partnership, Cancer, Good manufacturing practice, TSX, Safety, MES, Software, CGI, Organization, Fine chemical

The global partnership is designed to help clients increase efficiency, accuracy, and safety in pharma products and enhance decision-making through access to real-time data.

Key Points: 
  • The global partnership is designed to help clients increase efficiency, accuracy, and safety in pharma products and enhance decision-making through access to real-time data.
  • "CGI works side-by-side with clients to transform data into actionable insights to drive smart, sustainable and resilient operations," said Tim Hurlebaus President, U.S. Commercial & State Government operations and global executive sponsor for CGI's health and life sciences business.
  • Our partnership with Körber complements our offerings portfolio, enabling us to deliver innovative new services and solutions to support the needs of our pharma and life sciences clients."
  • "In our global client insights research , pharma and life sciences executives said optimizing operations is their top business priority.

Vitrolife AB (publ) announces changes in the Board of Directors

Retrieved on: 
Tuesday, August 1, 2023
Lykke, Audit committee, EQT, Management

The board member Vesa Koskinen, appointed by EQT VIII has at his own request chosen to resign from the Board of Directors of Vitrolife AB (publ).

Key Points: 
  • The board member Vesa Koskinen, appointed by EQT VIII has at his own request chosen to resign from the Board of Directors of Vitrolife AB (publ).
  • Vesa Koskinen has been a board member since 1 December 2021 and will step down as of today.
  • "On behalf of the board, I would like to thank Vesa Koskinen for his contributions during his time as a board member," says Jón Sigurdsson, Chairman of the Board of Vitrolife AB (publ).
  • After the announced changes, the Board consists of the Chairman of the Board Jón Sigurdsson and the board members Henrik Blomquist, Karen Lykke Sørensen, Lars Holmqvist and Pia Marions.

GIN MARE™ ANNOUNCES ALCHEMIST AS THE ART OF HOSPITALITY AWARD WINNER AT THE WORLD'S 50 BEST RESTAURANT AWARDS, VALENCIA

Retrieved on: 
Wednesday, June 21, 2023
Lykke, Alchemy, Restaurant, Hospitality Awarding Body, Ramsay's Best Restaurant, Best, Element, Science, Art, The Alchemist (musician), Content, Liquor, Entertainment

VALENCIA, Spain, June 21, 2023 /PRNewswire/ -- Gin Mare, the ultra premium gin and official gin partner of The World's 50 Best Restaurants, Valencia has named Alchemist, Copenhagen the winner of the Art of Hospitality Award.

Key Points: 
  • VALENCIA, Spain, June 21, 2023 /PRNewswire/ -- Gin Mare, the ultra premium gin and official gin partner of The World's 50 Best Restaurants, Valencia has named Alchemist, Copenhagen the winner of the Art of Hospitality Award.
  • The award was presented to Alchemist for redefining hospitality with its multi-sensory dining experience.
  • Alchemist takes over the No.1 spot from Atomix, New York who were presented the 2022 Art of Hospitality Award.
  • Alex Aves, Global Brand Director, Gin Mare says, "Gin Mare is built on sharing food, drinks, and welcoming hospitality.

GIN MARE™ ANNOUNCES ALCHEMIST AS THE ART OF HOSPITALITY AWARD WINNER AT THE WORLD'S 50 BEST RESTAURANT AWARDS, VALENCIA

Retrieved on: 
Wednesday, June 21, 2023
Lykke, Alchemy, Restaurant, Hospitality Awarding Body, Ramsay's Best Restaurant, Best, Element, Science, Art, The Alchemist (musician), Content, Liquor, Entertainment

VALENCIA, Spain, June 21, 2023 /PRNewswire/ -- Gin Mare, the ultra premium gin and official gin partner of The World's 50 Best Restaurants, Valencia has named Alchemist, Copenhagen the winner of the Art of Hospitality Award.

Key Points: 
  • VALENCIA, Spain, June 21, 2023 /PRNewswire/ -- Gin Mare, the ultra premium gin and official gin partner of The World's 50 Best Restaurants, Valencia has named Alchemist, Copenhagen the winner of the Art of Hospitality Award.
  • The award was presented to Alchemist for redefining hospitality with its multi-sensory dining experience.
  • Alchemist takes over the No.1 spot from Atomix, New York who were presented the 2022 Art of Hospitality Award.
  • Alex Aves, Global Brand Director, Gin Mare says, "Gin Mare is built on sharing food, drinks, and welcoming hospitality.

Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes

Retrieved on: 
Wednesday, December 7, 2022
Health, Diabetes, Clinical Trials, Research, Pharmaceutical, Science, Lykke, Eli Lilly and Company, Insulin, LLY, Ageing, Exercise, Linagliptin, Pediatrics, International Diabetes Federation, Risk, Adolescence, Empagliflozin, Prevalence, Fasting, Joslin Diabetes Center, NYSE, World Diabetes Day, Diabetes, International Maternal Pediatric Adolescent AIDS Clinical Trials Group, Type 2 diabetes, Obesity, Face, Multimedia, Diet, Metformin, Safety, SGLT2, Harvard Medical School, Boehringer Ingelheim, IDF, New product development, Pharmaceutical industry, Glycated hemoglobin

View the full release here: https://www.businesswire.com/news/home/20221207005405/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221207005405/en/
    The DINAMO (DIabetes study of liNAgliptin and eMpagliflozin in children and adOlescents) trial included youth aged 10-17 years with type 2 diabetes and HbA1c 6.5% and 10.5%.
  • Participants were randomly assigned treatment with empagliflozin (10 or 25 mg) (n=52), linagliptin (5 mg) (n=53) or placebo (n=53) once daily.
  • Todays results from the DINAMO global clinical trial demonstrated that the SGLT2 inhibitor empagliflozin compared with placebo significantly improved overall blood sugar control in children and adolescents with type 2 diabetes.
  • A numerical reduction of 0.34% (P=0.2935) was observed.1
    The findings have been submitted for publication in a peer-reviewed journal.

The First AI Exhibit at a National Gallery Launches in the Faroe Islands

Retrieved on: 
Tuesday, September 27, 2022
Lykke, Exhibition, Island, National Gallery, Computer, Life, Imagination, Language, History, Painting, Technology, Faroe Islands, Artificial intelligence, Collection, Multimedia, AI, Sheep, Nightclub, Whaling

NEW YORK, Sept. 27, 2022 /PRNewswire/ -- Today the National Gallery of the Faroe Islands launches an exhibition of 40 images created by the AI program Midjourney, making it the first time ever that a national gallery features a fully produced show created by artificial intelligence. Running September 29 through October 30, the exhibit reveals how the world's greatest artists could have depicted the landscape of this remote archipelago unreachable in their day. The intriguing AI images provide visitors the opportunity to experience how the likes of Van Gogh, Monet and Picasso would have painted the Faroe Islands.

Key Points: 
  • NEW YORK, Sept. 27, 2022 /PRNewswire/ -- Today the National Gallery of the Faroe Islands launches an exhibition of 40 images created by the AI program Midjourney, making it the first time ever that a national gallery features a fully produced show created by artificial intelligence.
  • The intriguing AI images provide visitors the opportunity to experience how the likes of Van Gogh, Monet and Picasso would have painted the Faroe Islands.
  • Please see works of the many gifted Faroese artists at the National Gallery of the Faroe Islands' homepage, www.art.fo .
  • The Faroe Islands might be small, but nature works on a grand scale on the 18 islands in the North Atlantic.

Zealand Pharma Appoints Henriette Wennicke as Chief Financial Officer

Retrieved on: 
Wednesday, August 24, 2022
Lykke, AstraZeneca, Accounting, COVID-19, GN, Advertising, Research, DK, Solution, R, Novo Nordisk, Nasdaq Copenhagen, Organization, Zealand Pharma, CFO, Treasury, GN Store Nord, Copenhagen Business School, Leadership, Nasdaq, Failure, Boehringer Ingelheim, Intellectual property, Private Securities Litigation Reform Act, Patient, Pharmaceutical industry, Management, Fine chemical

20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Henriette Wennicke as Zealands Chief Financial Officer starting November 1, 2022.

Key Points: 
  • 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Henriette Wennicke as Zealands Chief Financial Officer starting November 1, 2022.
  • Henriette Wennicke comes to Zealand with broad finance and business experience at large organizations, including in healthcare, where she has led financial planning and R&D portfolio management.
  • Henriette brings a track record of leadership in finance and business strategy, and we are thrilled to welcome her to Zealand at this important juncture for the company, said Adam Steensberg, Chief Executive Officer, Zealand Pharma.
  • I am excited and honored to be joining Zealand Pharma, and delighted to be returning to the healthcare industry, said Henriette Wennicke.